Med-X Company Updates

In this important video update, CEO, Matthew Mills discusses how the company will be ending its Regulation A+ crowdfunding initiative. On April 22nd, 2022 at 11:59PM PST, Med-X, Inc. investor platform “www.medxinvestor.com” will be closed and no longer be available for investors to participate in the Company’s crowdfunding efforts. Please watch the video to find out details about the offering closing and more. 

In this company update, CEO, Matthew Mills informs the shareholders on the new relationship with Investor Relations Firm MZ North America. Matthew informs the shareholders on the company's continued focus to gain access to the $100 Million in capital from GEM. Matthew also discusses changes to the Board of Directors as well as an update on international sales and marketing opportunities.

LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Med-X, Inc. (Med-X) announced that in October 2021 the Company received Patent No. 11,147,266 B2 for its Nature-Cide Insecticidal Soil formulation. What started as a soil application for the cannabis industry in 2016 has blossomed into a multi-use soil blend for all types of cultivation, from greenhouse and agricultural applications to cannabis/hemp operations.

In this very important video update COO and President, Matthew Mills informs the shareholders on the positioning and the preparation to list the Company on a national exchange to access the $100 million capital commitment for expansion that's waiting in the open market for the Company. Matthew is actively engaging in discussions with the investment banking community to help support our efforts to make this goal a reality.  Please watch the video and read the formal press release below.

LOS ANGELES, Aug. 6, 2021 /PRNewswire/ -- Today, Med-X, Inc. (MED-X) announced a $100 million capital commitment from GEM Global Yield, LLC SCS (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to $100 million for a 36-month term following the public listing of MED-X's common stock. Med-X will control the timing and maximum number of drawdowns and under this agreement can put a drawdown notice for up to $10MM worth of shares on the first day of trading. Concurrent with a public listing Med-X will issue warrants to GEM to purchase up to 4.0% of the common stock of the company. Med-X's flagship division, Nature-Cide, has developed a line of all-natural professional pest control applications. One of its pest control solutions for Vector Control, is continuously being tested by third parties with astounding recorded results. The products are set for expansion, from major distribution partners in in various regions around the globe. "GEM's equity investment solidifies our business model as well as our long-term financial goals while reinforcing and furthering our mission to the world stage", states founder and COO Matthew Mills. "So far, we've been very successful with self-underwriting our Regulation A+ Offering, which has generated investments from more than 3,600 individuals over the last 4 years. This new $100MM capital commitment should allow the Company to advance on its Mergers & Acquisitions strategy, while propelling the brands in a manner where our mission of "Making a difference every day" will move to a whole new level", states Mills.  Live PR - https://www.marketwatch.com/press-release/med-x-inc-secures-100-million-expansion-capital-commitment-from-global-emerging-markets-gem-2021-08-06 About Med-X, Inc. Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand.  For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870 About The GEM Global Yield, LLC SCS Group   About GEM Global Emerging Markets ('GEM') is a $3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments. For more information: https://www.gemny.com GEM Contact: Jean-Luc Bonnefoy: jbonnefoy@gemny.com   Med-X Contact Matthew Mills: matt@medx-rx.com DISCLAIMER AND FORWARD-LOOKING STATEMENTS The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular Securities Exchange Commission filings before making any investment in the Company.  This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events. SOURCE Med-X, Inc.

In this exciting Company update, COO and President, Matthew Mills informs shareholders on the status of several international deals, status of ecommerce growth, capital raising and announces an exciting signing of the Company's first non-binding Term Sheet with an investment bank for an 86 Million dollar equity drawdown, to support the Company’s growth initiatives, if and when the Company lists on a public exchange.      Growth in our digital ecommerce sales efforts continues its pace forward. New initiatives have recently been executed to continue to bolster B2C sales including the approval from Walmart Marketplace to enter the Walmart Fulfillment program.  Walmart is very selective when it comes to approving brands and companies to be included in this program, so we feel very confident that our products and customer service is making a difference in our customers' lives. Walmart is recognizing us, which is great news for our brands.   Walmart advertises to its fulfillment partners that customers should expect a 20% to 40% increase in sales by simply entering the program. We will keep you updated on this front in future updates as our team continues to dial this all in.  Progress also continues to be made on our international Nature-Cide positioning as the labels are currently under review to get approved by the Mexican and Australian governmental authorities. Products have already shipped to Terminix in the Caribbean and Antigua. The compliance and approval processes are critical for our growth internationally but our partners have a solid track record of bringing in new products, and we feel really good about the coming months as we continue to push through the red tape.  Matthew continues to speak with dozens of interested investment entities including VC’s, Angel investors, Family Offices and Investment Banks. Our partners at New Chip as well as our new broker-dealer, The Dalmore Group, have been actively making strong recommendations and introductions as the management team works tirelessly to find the right fit to assist our efforts to potentially take the Company to the public market.  Matthew has also initially agreed to an 86 Million dollar non-binding term sheet with a large investment bank who is committed to seeing our Company grow and bolster revenue once the Company is listed. At this point, the Company fits all the criteria to list on the Nasdaq except for one item. We need an additional $4 million dollars in the bank to fully qualify. Many of our Accredited investors have recognized this opportunity and they have stepped up in a big way to support this mission.  This money is required so the Company can bridge the gap from private to public, as Matthew explains in the video. “We are finally in a position where our business is of interest to the investment banking community, and we will continue pushing to line up the right partners. One thing we have learned over the years is to have as many irons in the fire as possible on all fronts. It’s inevitable that some of the relationships will flourish, and others will fizzle and not perform as expected. So, the only way we can move forward is to build an abundance of relationships amongst all of the inner workings of our business, until we find all the right performers,” states Matthew.     We are hopeful that all of our shareholders will also recognize this opportunity and spread the word by telling their friends, family and co-workers about our Company and how they can also get involved and get in on the ground floor before we potentially file for a listing on a public exchange.  As Matthew also says in the video, this is an exciting time and all of your support and the hard work from our team has really set the Company up for success and is setting a path for our goals. We would never be in this position without all the support from each and every one of our shareholders.  We thank you. We are all so grateful to have such an amazing group of people connected to this Company who support all of our work.  Also, please double-check your investor dashboard to make sure everything is matching up with your records. As we get closer to our end goal it will be critical that your contact information and investment information is accurate. Contact us if you notice any discrepancies.  SEC FIling - https://www.sec.gov/Archives/edgar/data/1620704/000147793221002683/medx_1k.htm Thank you very much. Med-X Team DISCLAIMER AND FORWARD-LOOKING STATEMENTS  The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.  This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

In this company video update President and COO, Matthew Mills discusses the company's continued progress with E-Commerce distribution as well as the momentum that continues building with multiple investment banking opportunities including a new promising investment banker / broker-dealer relationship.

In this video update on January 22,  2021, COO and President, Matthew Mills reports to all shareholders on the revenue momentum that is carrying over into 2021. He explains in detail why the Company is having its best January in its history as well as discusses some exciting news in regarding the details, including our new relationships that are bringing the Nature-Cide products into Mexico, Australia, Sri Lanka and the Caribbean.  There are a lot of moving parts with this business, so please watch the video and check the news and updates section in your investor dashboard regularly, as communications will be increasing as the Company moves forward.   We are excited to report that revenue is exceeding our expectations already this year. This is the best start to a year the Company has had and we are hopeful this is setting the tone for the rest of the year.

In this video update, COO and President, Matthew Mills reviews the year-end Company progress and outlines how this momentum will potentially set the Company up in 2021. 2020 was a challenging year for everyone including Med-X. We faced all the challenges head-on and even during this global pandemic, of the likes few living people have ever endured, we still balanced the Company and grew revenue to over 1 million dollars. 

In this video to all Med-X shareholders, President and COO, Matthew Mills gets up close and personal and discusses how all investors need to be organized and involved in the direction of the Company, as it accelerates into 2021.  As Matthew discusses the various entities that are aligning with the Company and its multiple divisions, he is reminded of, and shares the past experience of a pathway of a previous public listing, and makes it very clear that ALL shareholders need to make sure their online portal dashboard accounts are in order.  Additionally, the Company management team and general counsel are preparing and organizing the Company in a manner where a listing on a public exchange could go hand in hand with large scale financing and acquisitions during the process.  It's very clear to management that agility is everything, and a multitude of options are seemingly presenting themselves from the multiple relationships that are building up around the Company. To reiterate, this is another reason to make sure your stock account is in order.  Please watch the video before you read the rest of this.      As we continue to plan the pathway to a possible listing of the Company on a national stock exchange, we want to make it clear and keep repeating this…